A joint venture by Sony and Olympus, which makes medical equipment, will now proceed after the deal was delayed pending approval from China’s competition authority. The companies announced that they have now received all necessarily approval. Sony is investing $535 million into Olympus in efforts to increase its competitive stance within the medical equipment market. Olympus dominates about 70 percent of the sector, according to reports, despite being more well-known for its camera products. Additionally, while the two companies did not say which specific competition regulator was delaying the deal, sources confirmed to the media that it was China’s authority. The parties had originally planned to launch the venture on April 1.
Featured News
Following EU, Canada Unveils AI Sovereignty Plan
Jun 5, 2026 by
CPI
New Coalition Targets Legal Framework for Public-Private Cyber Operations
Jun 5, 2026 by
CPI
EU Pauses Review of UPM-Sappi’s €1.42 Billion Paper Venture
Jun 4, 2026 by
CPI
Bipartisan House Lawmakers Unveil Draft Bill to Limit State Regulation of AI
Jun 4, 2026 by
CPI
Paramount Moves to Throw Out Consumer Challenge to Warner Bros. Discovery Acquisition
Jun 4, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – (Geo)Political Antitrust
May 28, 2026 by
CPI
Competition Policy in Turbulent Geopolitical Times
May 28, 2026 by
Christophe Carugati & Annabelle Gawer
The New Political Determinants of U.S. Antitrust Policy
May 28, 2026 by
Aziz Z. Huq
The Geopolitical Rewiring of Antitrust
May 28, 2026 by
Hayane C. Dahmen
Three Strikes Against Political Antitrust
May 28, 2026 by
Nolan McCarty & Sepehr Shahshahani